227 related articles for article (PubMed ID: 38311708)
1. Targeting BRCA and PALB2 in Pancreatic Cancer.
Anbil S; Reiss KA
Curr Treat Options Oncol; 2024 Mar; 25(3):346-363. PubMed ID: 38311708
[TBL] [Abstract][Full Text] [Related]
2. The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib.
Brown TJ; Yablonovitch A; Till JE; Yen J; Kiedrowski LA; Hood R; O'Hara MH; Teitelbaum U; Karasic TB; Schneider C; Carpenter EL; Nathanson K; Domchek SM; Reiss KA
Clin Cancer Res; 2023 Dec; 29(24):5207-5216. PubMed ID: 37486343
[TBL] [Abstract][Full Text] [Related]
3. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in
Reiss KA; Mick R; O'Hara MH; Teitelbaum U; Karasic TB; Schneider C; Cowden S; Southwell T; Romeo J; Izgur N; Hannan ZM; Tondon R; Nathanson K; Vonderheide RH; Wattenberg MM; Beatty G; Domchek SM
J Clin Oncol; 2021 Aug; 39(22):2497-2505. PubMed ID: 33970687
[TBL] [Abstract][Full Text] [Related]
4. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
[TBL] [Abstract][Full Text] [Related]
5. Molecular characteristics of
Seeber A; Zimmer K; Kocher F; Puccini A; Xiu J; Nabhan C; Elliott A; Goldberg RM; Grothey A; Shields AF; Battaglin F; El-Deiry WS; Philip PA; Marshall JL; Hall M; Korn WM; Lenz HJ; Wolf D; Feistritzer C; Spizzo G
ESMO Open; 2020 Nov; 5(6):e000942. PubMed ID: 33229504
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
Konecny GE; Kristeleit RS
Br J Cancer; 2016 Nov; 115(10):1157-1173. PubMed ID: 27736844
[TBL] [Abstract][Full Text] [Related]
7. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
Johnson N; Johnson SF; Yao W; Li YC; Choi YE; Bernhardy AJ; Wang Y; Capelletti M; Sarosiek KA; Moreau LA; Chowdhury D; Wickramanayake A; Harrell MI; Liu JF; D'Andrea AD; Miron A; Swisher EM; Shapiro GI
Proc Natl Acad Sci U S A; 2013 Oct; 110(42):17041-6. PubMed ID: 24085845
[TBL] [Abstract][Full Text] [Related]
8. Clinical Use of PARP Inhibitors in BRCA Mutant and Non-BRCA Mutant Breast Cancer.
Lynce F; Robson M
Cancer Treat Res; 2023; 186():91-102. PubMed ID: 37978132
[TBL] [Abstract][Full Text] [Related]
9. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
Pishvaian MJ; Biankin AV; Bailey P; Chang DK; Laheru D; Wolfgang CL; Brody JR
Br J Cancer; 2017 Apr; 116(8):1021-1026. PubMed ID: 28291774
[TBL] [Abstract][Full Text] [Related]
10. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
Moffat GT; O'Reilly EM
Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
[TBL] [Abstract][Full Text] [Related]
11. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
12. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
13. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
Onstad M; Coleman RL; Westin SN
Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
[TBL] [Abstract][Full Text] [Related]
14. Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains.
Park D; Shakya R; Koivisto C; Pitarresi JR; Szabolcs M; Kladney R; Hadjis A; Mace TA; Ludwig T
PLoS One; 2019; 14(12):e0226714. PubMed ID: 31877165
[TBL] [Abstract][Full Text] [Related]
15. BRCA1/2 reversion mutations in a pan-cancer cohort.
Nakamura K; Hayashi H; Kawano R; Ishikawa M; Aimono E; Mizuno T; Kuroda H; Kojima Y; Niikura N; Kawanishi A; Takeshita K; Suzuki S; Ueno S; Okuwaki K; Sasaki J; Yamaguchi M; Masuda K; Chiyoda T; Yamagami W; Okada C; Nohara S; Tanishima S; Nishihara H
Cancer Sci; 2024 Feb; 115(2):635-647. PubMed ID: 38041241
[TBL] [Abstract][Full Text] [Related]
16. PARP-inhibitors in BRCA-associated pancreatic cancer.
Bhalla A; Saif MW
JOP; 2014 Jul; 15(4):340-3. PubMed ID: 25076338
[TBL] [Abstract][Full Text] [Related]
17. Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer.
Pham MM; Avila M; Hinchcliff E; Westin SN
Cancer Treat Res; 2023; 186():71-89. PubMed ID: 37978131
[TBL] [Abstract][Full Text] [Related]
18. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
19. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Kurnit KC; Coleman RL; Westin SN
Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
[TBL] [Abstract][Full Text] [Related]
20.
Darabi S; Braxton DR; Xiu J; Carneiro BA; Swensen J; Antonarakis ES; Liu SV; McKay RR; Spetzler D; El-Deiry WS; Demeure MJ
Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557020
[No Abstract] [Full Text] [Related]
[Next] [New Search]
